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Abstract
For 21 putative BRCA1 and BRCA2 splice site variants, the concordance between mRNA analysis
and predictions by in silico programswas evaluated. Aberrant splicing was confirmed for 12 alter-
ations. In silico prediction toolswerehelpful to determine forwhich variants cDNAanalysis iswar-
ranted, however, predictions for variants in the Cartegni consensus region but outside the canon-
ical sites, were less reliable. Learning algorithms like Adaboost and Random Forest outperformed
the classical tools. Further validations are warranted prior to implementation of these novel tools
in clinical settings. Additionally, we report here for the first time activated cryptic donor sites in
the large exon 11 of BRCA2 by evaluating the effect at the cDNA level of a novel tandem dupli-
cation (5′ breakpoint in intron 4; 3′ breakpoint in exon 11) and of a variant disrupting the splice
donor site of exon 11 (c.6841+1G > C). Additional sites were predicted, but not activated. These
sites warrant further research to increase our knowledge on cis and trans acting factors involved
in the conservation of correct transcription of this large exon. This may contribute to adequate
design of ASOs (antisense oligonucleotides), an emerging therapy to render cancer cells sensitive
to PARP inhibitor and platinum therapies.
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1 INTRODUCTION
The risk of breast and ovarian cancer increases drastically in indi-
viduals carrying a germline BRCA1 (MIM# 113705) or BRCA2 (MIM#
600185) mutation. Heterozygous pathogenic mutations are associ-
ated with a lifetime risk of 50%–80% for breast cancer and 30%–
50% for ovarian cancer (Roy, Chun, & Powell, 2012). However, due
to an evolution in sequencing technologies, the number of individuals
undergoing screening drastically increased and this led to a significant
rise in the number of variants of unknown clinical significance (VUS).
The detection of a VUS is a challenge for healthcare providers as the
impact on the risk for breast or ovarian cancer risk is unclear (Goldgar
et al., 2004). For missense variants, a number of functional tests have
been proposed (e.g., Hendriks et al., 2014; Millot, Carvalho, Caputo, &
Vreeswijk, 2012), but the implementation on a large scale in a clinical
diagnostic setting is not feasible. In contrast,mRNAanalyses to investi-
gate intronic andexonic variants thatmight impair properRNAsplicing
are more widely used. The effect of putative splice site variants can be
evaluated in silico as a wide variety of tools have been developed (Jian,
Boerwinkle, & Liu, 2014b). Indeed, variants in the highly conserved
dinucleotides at the splice site donor/acceptor sites at the intron
boundaries, in the conserved adjacent sequences or variants in the
branchpoints and exonic splicing enhancers (ESE) might lead to aber-
rant splicing (Houdayer et al., 2012; Spurdle, Couch, Hogervorst,
Radice, & Sinilnikova, 2008; Strachan&Read, 2010). Several guidelines
havebeen formulated toassist thedecision-makingprocess (Caminsky,
Mucaki, & Rogan, 2014; Houdayer et al., 2008; Tang, Prosser, & Love,
2016). Accurate prediction by these tools is dependent on the ability
to detect the wild-type (WT) splice site or define regions such as the
branchpoints or ESE. Furthermore, it depends on the degree of conser-
vation of the region in which the variant is situated (Caminsky et al.,
2014). Several in silico prediction tools have previously been exten-
sively validated for the prediction of aberrant splicing (Caminsky et al.,
2014; Houdayer et al., 2008; Tang et al., 2016). Themajor problem that
complicates the use of these tools in diagnostic laboratories is that
there is no unified standard to measure how splicing signals change
when one allele is substituted by another becausemost tools only out-
put prediction scores for potential splice sites given an input DNA
sequence. Due to complex dependencies existing among the bases
around splice sites, none of the frequently used programs perfectly
predict the impact on pre-mRNA splicing. Learning algorithms such as
AdaBoost (Pashaei, Yilmaz, Ozen, & Aydin, 2016) and Random Forest
(Meher, Sahu, & Rao, 2016) are now emerging and need to be validated
for their use in research and clinical practice.
For the evaluation of the effect of exonic variants on splicing, ESE-
specific in silico prediction tools such as ESEfinder (Cartegni, Wang,
Zhu, Zhang, & Krainer, 2003), RESCUE-ESE (Fairbrother, Yeh, & Sharp,
2002), and the quantitative evaluation of hexamers as exonic splicing
elements (Ke et al., 2011) can be applied.
In this study we evaluated the concordance between “classic pre-
diction tools” and more recently developed algorithms (AdaBoost and
Random Forest) for 11 BRCA1 and 10 BRCA2 variants. Especially for
variants outside the canonical splice sites (±1, ±2), the frequently
applied prediction tools are less adequate (Spurdle et al., 2008). We
compared the in silico output with data of in vitro RNA splicing assays
in short-term cultured peripheral blood lymphocytes of patients het-
erozygous for the variants.
In addition, we evaluated the effect at the cDNA level of a novel
large tandem duplication spanning exons 5 to a large part of exon 11
in BRCA2.We found that besides a skip of the exon, two cryptic donor
siteswereactivatedwithin exon11.Weconfirmed that thesewerealso
activated in a patientwith an interrupted donor site due to aG>Csub-
stitution at position+1 of intron 11.
2 MATERIALS AND METHODS
2.1 Variant selection
Eleven DNA alterations in BRCA1 and 10 in BRCA2 were selected for
this study (Supp. Table S1). In addition, we investigated the effect of
a large duplication in BRCA2 at the cDNA level. Some variants have
entries in the ClinVar or LOVD databases, but no assays to eluci-
date splicing effects were previously reported and their pathogenicity
remained unclear.
We submitted all variants described in this paper to
the LOVD databases for BRCA1 and BRCA2 variants (URL:
https://databases.lovd.nl/shared/genes/BRCA1 and https://databases
.lovd.nl/shared/genes/BRCA2).
2.2 In silico prediction
Five prediction tools integrated in Alamut R© Visual 2.8.1 (Interactive
Biosoftware, Rouen, France) were used to assess the impact of the
variants on splice sites in silico: MaxEntScan (MES), Human Splicing
Finder, Splice Site Finder (SSF), Splice Site Prediction by Neural Net-
work, and GeneSplicer. In Supp. Table S2, the main references and pre-
viously determined cut-offs of these programs can be found.
Furthermore, we consulted the dbscSNV v1.1 database for
Adaboost and RandomForest scores. A score higher than 0.6 is
indicative for aberrant splicing (Jian, Boerwinkle, & Liu, 2014a).
All variants located in the coding regions were also evaluated for
their effect on ESE. Disruptions of these 6 bp motifs can result in
improper splicing and can be predicted by tools such as ESEFinder
(Cartegni et al., 2003) and RESCUE-ESE (Fairbrother et al., 2002),
both integrated in Alamut R© Visual 2.8.1. The quantitative evalua-
tion of all RNA hexamers as potential exonic splicing elements (Ke
et al., 2011) was used to calculate total exonic splicing regulatory
sequence (ESRseq) score change (∆ESRseq scores) for every exonic
variant. Through analysis of variants inBRCA2 exon7,DiGiacomoet al.
(2013) experimentally determined a cut-off of −0.663 (Di Giacomo
et al., 2013).
Finally, for variants in the coding regions the effect of amino acid
substitution itself should also be taken into account. Therefore, Priors
(https://priors.hci.utah.edu/PRIORS/), an online tool combining amino
acid substitution severity and spliceogenecity-based probability for
pathogenicity ofBRCA1 andBRCA2pointmutationswas also consulted
(Vallée et al., 2016).
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2.3 Sample collection, cell cultures, RNA isolation,
and cDNA preparation
Individuals with variants of interest donated a blood sample in
EDTA tubes and signed an informed consent. From these blood sam-
ples, phytohemagglutinin stimulated short-term lymphocyte cultures
were established (Messiaen & Wimmer, 2008). At day 7, puromycin
(200 �g/ml; Sigma–Aldrich, St. Louis, Missouri, USA) was added to the
cultures to avoid nonsense-mediated decay (NMD). Four to six hours
later, total RNA was extracted using the QIAamp R© RNeasy Mini Kit
(QIAGEN, Venlo, The Netherlands) according to the manufacturer's
instructions. cDNA was synthesized using either the iScriptTM cDNA
Synthesis Kit (Bio-Rad Laboratories, Hercules, California, USA) or the
Superscript R© II ReverseTranscriptaseKit (LifeTechnologies,Carlsbad,
California, USA).
2.4 RT-PCR and sequencing
Splicing aberrations were assessed by means of RT-PCR using either
primers in separate exons or primers situated at the exon bound-
aries (Supp. Table S3) to avoid genomic DNA interference. Frag-
ment sizes were checked on the Labchip GX (Caliper Life Sciences,
Waltham, Massachusetts, USA) or on agarose gel. Sanger sequencing
was performed using the BigDye R© Terminator Cycle Sequencing Kit
(Life Technologies, Carlsbad, California, USA). Transcripts from car-
riers were compared to at least three controls for RT-PCR and at
least one control was included for sequencing analysis. For analysis of
the BRCA1 variant c.4675+3A > T, cloning was performed using the
TA CloningTM kit (ThermoFisher Scientific, Waltham, Massachusetts,
USA) to characterize the various aberrant transcripts revealed
by RT-PCR.
2.5 Nomenclature
Nucleotide and exon numbering for cDNA is based on NCBI entries
NM_007294.3 (BRCA1) and NM_000059.3 (BRCA2). Nucleotide +1
corresponds to A of AUG translation initiation codon (according to
HGVS guidelines). NM_007294.3 omits the historical exon 4 and
renumbers the remaining exons sequentially (Ensembl transcript:
ENST00000357654.7). In Supp. Table S1, the “legacy numbering" is
also provided.
3 RESULTS
An overview of the BRCA1 and BRCA2 variants evaluated can be found
in Supp. Table S1, including in silico prediction data as well as the
results of cDNA analysis in short-term cultured lymphocytes in the
presence of puromycin. Out of 21 tested DNA alterations, 12 DNA
alterations (seven BRCA1 and five BRCA2 variants) resulted in one or
more aberrantmRNA transcripts. Furthermore, theBRCA2 duplication
c.425+415_4780dup{ins GATCGCAGTGA}, spanning exons 5, 6, 7, 8,
9, 10, and a large part of exon 11, was shown to result in a complex
splicing pattern.
3.1 cDNA analysis results for four variants
in canonical splice sites
BRCA1 c.5468-1G > A is located in the splice acceptor site of the last
coding exon 23. Loss of the WT splice site, unanimously predicted by
all prediction tools (Supp. Table S1), results in an out of frame deletion
of the first 11 bp of exon 23 as a cryptic splice site acceptor was acti-
vated 11 bp downstream of the WT acceptor site. This resulted in an
aberrant transcript (r.5468_5478del), leading to a premature termina-
tion codon (PTC) (p.(Ala1823Valfs*2)) (Figure 1A). We cannot rule out
that this variant also leads to loss of exon 23, the last exon of BRCA1, as
we have nomeans to design primers in the next exon.
The substitution BRCA1 c.4986+1G > C results in the activation of
a cryptic splice site at c.4986+65. This leads to an aberrant transcript
in which the first 65 intronic nucleotides of intron 15 are retained:
r.4986_4987ins4986+1_486+65, p.(1662Phefs*14) (Figure 1B).
BRCA1 c.5152+2dupT inactivates the splice donor site of exon 17,
resulting in an aberrant transcript lacking exon 17 (r.5075_5152del;
p.(Asp1692_Trp1718delinsGly)) (Figure 1C).
BRCA2 c.6841+1G > C results in the abolishment of the WT
splice donor site of exon 11, accurately predicted by all tools. This
leads to multiple aberrant transcripts of which a skip of exon 11
(r.1910_6841del, p.(Leu638_Gly2281del)) is the most abundant (Fig-
ure 2A–C). However, additional isoforms are obvious from Figure 2A.
These are further described under point 3.4.
3.2 cDNA analysis results for 10 variants outside
the canonical splice sites but in the Cartegni consensus
region
The Cartegni consensus region encompasses 11 bases of the 5′ splice
site (from the three last exonic to the eight first intronic bases) and 14
bases of the 3′ site (from the 12 last intronic to the first two exonic
bases) (Cartegni, Chew, & Krainer, 2002).
Two exonic variants in this region both result in aberrant splicing:
- The substitution BRCA1 c.4674A > G, affecting the second last
nucleotide of exon 14, leads to the abolishment of the natural splice
donor site as predicted by all in silico tools. The lack of a natural
splice donor site resulted in the activation of a cryptic splice site at
position c.4664, only predicted by SSF (score = 91.56), leading to
a deletion of the last 11 nucleotides of exon 14: r.4665_4675del;
p.(Gln1556Glyfs*14). The presence of a small “G” signal at posi-
tion c.4674, demonstrates some remaining activity from the natural
splice site (Supp. Table S1 and Figure 1D).
- BRCA2 c.517G > C, located in the first nucleotide of exon 7 leads
to an aberrant transcript containing an out of frame skip of exon
7 (r.517_631del; p.(Gly173Serfs*19)) due to the inactivation of the
WT splice donor (Supp. Table S1 and Figure 4A). MES provided a
small reduction in score (−12.1%, lower than the 15% cut-off previ-
ously proposed by Houdayer et al. (2012) and Jian et al. (2014a), but
higher than the 10% cut-off more recently proposed by Tang et al.
(2016)). Priors calculated a greater change of pathogenicity through
splicing defects (probability = 0.34) than as to be expected from the
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F IGURE 1 Results of in vitro mRNA analysis of six BRCA1 variants leading to aberrant splicing. Schematic representation of six BRCA1 variants
leading to aberrant splicing with x illustrating the position of the variant. Sequencing results are shown for the patient with the mutation and a
negative control. From panel E, it is clear that r.-25_-20del represents a major alternative splice event, observed in both the patient and controls
(Colombo et al., 2014;Menéndez et al., 2012). Nucleotide and exon numbering for cDNA is based onNCBI entry NM_007294.3
missense variant itself (probability= 0.02). Only AdaBoost and Ran-
dom Forest provided high scores indicative for aberrant splicing.
Five out of eight intronic variants in the Cartegni consensus region
resulted in aberrant splicing and in silico predictions for these variants
were accurate: BRCA1c.80+5G > A, c.134+5G > T & c.4675+3A > T,
and BRCA2 c.8488-9T>G& c.8954-5A>G.
- BRCA1 c.80+5G > A abolishes the WT donor site of exon 2.
With primers located in the non-coding exon 1 and in exon 7, we
found that this variant leads to out of frame skipping of exon 2
(r.-19_80del; p.?) leading to loss of the translation initiation codon
(Supp. Table S1 and Figure 1E). In addition, we found both in the
controls and the patient with the mutation an abundant alter-
native transcript (r.-25_-20del: skip of the last six nucleotides of
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F IGURE 2 Schematic representation of the results of in vitro mRNA analysis for the BRCA2 variant c.6841+1G > C. A–C: RT-PCR products on
agarosegel, schematic representation, and sequencingdata fromPCRproducts generatedwithprimers spanningexons10 to14 for thepatientwith
the c.6841+1G > C variant and four controls. In both the patient with the c.6841+1G > C mutation and the controls, several shorter transcripts
were observed (A). The full-length transcript (B) is present in all control samples, while the skip of exon 11 (c) is highly abundant in the patient
but shows lower expression in controls. ddPCR showed that this transcript represented <1% of the transcripts in controls (the “relatively strong”
band on the picture may be due to preferential amplification of the shorter transcript). D and E: Two additional isoforms were characterized. D:
A transcript resulting from the activation of a cryptic splice site donor at c.2398, missing nucleotides c.2399_6841 from exon 11 and (E) a slightly
longer transcript generated by the activation of a cryptic splice site donor at c.3550, lacking nucleotides c.3551_6841 from exon 11. Nucleotide
and exon numbering for cDNA is based onNCBI entry NM_000059.3
exon 1), which has previously been described as naturally occurring
isoform.
- BRCA1 c.134+5G > T inactivates the donor of exon 3 leading to
an out of frame skip of exon 3, resulting in a PTC: r.81_134del;
p.(Cys27*) (Figure 1F). Skipping of exon 3 has previously been
describedas anaturally occurring isoform (Colomboet al., 2014), but
fromFigure1F it becomes clear that this isoform is hardlydetectable
in controls compared to the patient with the c.134+5G > T
substitution.
- RT-PCR with primers located in exons 11–16 resulted in a smear of
PCR products on agarose gel for the patient with the BRCA1 variant
c.4675+3A>T,wherein the two tested controls only a single bandof
the expected length was observed (data not shown). To analyze the
products of different lengths, cloning followed by sequencing was
performed for 57 clones. Two heterozygous SNPs (c.4308T/C and
c.4837A/G) allowed to determine if the transcript originated from
the WT or the mutant allele. An overview of the aberrant mRNA
transcripts is shown in Figure 3 and Table 1; Sanger sequencing
results can be found in Supp. Figure S1. The major effect of this
mutation is the activation of a cryptic donor site, 11 nucleotides
upstream of theWT donor site of exon 14, similar as for the patient
with c.4674A > G. In addition, increased expression of the naturally
occurring isoform lackingexon14 (outof frame)wasobserved. Inter-
estingly, we have no evidence that this represents a major splice
event in the patient with c.4674A > G, in the second last nucleotide
of exon14.However, for analysis of this patient adifferentprimer set
to generate a shorter fragmentwas used (Supp. Table S3) and cloning
was not performed in that case.
- BRCA2 c.8954-5A > G (Figure 4B) was found to generate a
cryptic splice site, resulting in an out of frame insertion of
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F IGURE 3 Schematic representation of all isoforms obtained by primers located in exons 11 and 16 for BRCA1 c.4675+3A > T. Cloning of the
cDNA fragment revealed several different isoforms transcribed both from the mutant as well as from the WT allele. A schematic representation
of the different isoforms is shown (A–E). Corresponding Sanger sequencing results can be viewed in Supp. Figure S1. The x indicates the position
of the mutation. Panel (e) shows two minor alternative isoforms: an in frame insertion of 66 nucleotides (r.4357_4358ins4358-2785_4358-2720,
previously reported by our group Claes et al. (2003) and by Colombo et al. (2014)) in addition to an insertion of 63 nucleotides from intron 13
(r.4357_4358ins4358-2785_4358-2723, NCBI RefSeq NM_007300.3) representing less than 2% of the transcripts based on our cloning data
TABLE 1 Overview of aberrant transcripts detected for BRCA1 c.4675+3A> T
Transcript RNA Protein
% (Number of
clones/total
sequenced)
%Originating
from theWT
allele Figure 3
Full length / / 43.90%
(25/57)
96% (24/25) /
Out of frame skip of exon
14
r.4485_4675del p.Ser1496Glyfs*14 24.60%
(14/57)
7% (1/14) A
Out of frame deletion of
last 11 nucleotides of
exon 14
r.4665_4675del p.Gln1556Glyfs*14 17.50%
(10/57)
0% (0/10) B
In frame skip of exon 13
and 14
r.4358_4675del p.Ala1453_Leu1558del 3.50% (2/57) 0% (0/2) C
Out of frame skip of exon
13 and the last 11
nucleotides of exon 14
r.4358_4484del+
r.4665_4675del
p.Ala1453Gyfs*10 3.50% (2/57) 0% (0/2) D
Full length and insertion
of 66 nucleotides from
intron 12
r.4357_4358ins4358-
2785_4358-2720
p.Lys1452_Ala1453ins(22) 3.50% (2/57) 100% (2/2) E
Full length+ insertion of
63 nucleotides from
intron 12
r.4357_4358ins4358-
2785_4358-2723
p.Lys1452_Ala1453ins(21) 1.70% (1/57) 100% (1/1) E
Insertion of 66
nucleotides from
intron 12+ skip of
exon 14
r.4357_4358ins4358-
2785_4358-2720+
r.4485_4675del
p.Lys1452_Ala1453ins(22)
+ p.Ser1496Glyfs*14
1.70% (1/57) 100% (1/1) F
four nucleotides from intron 22 (r.8953_8954ins8954-4_8954-1;
p.(Val2985Aspfs*34)), inducing a premature stop codon, and there-
fore, prone to NMD.
- The outcome of two variants in the Cartegni site of BRCA2 intron
19 was different, which was accurately predicted by all in silico
prediction tools (Supp. Table S1). BRCA2 c.8488-9T > G creates
a cryptic acceptor site, leading to an aberrant transcript with an
out of frame insertion of the last eight nucleotides of intron 19
(r.8487_8488ins8488-8_8488-1; p.(Trp2830Tyrfs*36)) (Supp. Table
S1 and Figure 4C), whereasBRCA2 c.8488-12A>Gwas not found to
induce aberrant splicing.
- Also three other intronic variants in the Cartegni consensus region
(BRCA1 c.4186-10G>AandBRCA2 c.7618-6G>T; c.8488-12A>G)
did not result in aberrant splicing. Based on the MES predic-
tions, aberrant splicing for BRCA1 c.4186-10G > A (−17.7%) and
BRCA2 c.8488-12A > G (−13.7%) could be expected based on the
−10% cut-off proposed by Tang et al. (2016), whereas Houdayer
et al. (2012) applied a more stringent cut-off of −15%. For BRCA2
c.7618-6G > T, the classic splice prediction tools showed increased
scores for the natural acceptor site, compatible with normal
splicing.
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3.3 cDNA analysis results for seven variants outside
the Cartegni consensus region
We evaluated the effect at the mRNA level of two intronic variants
BRCA1 c.5278-22C>G and BRCA2 c.8488-14A>G.
- BRCA1 c.5278-22C>Gdid not result in aberrant splicing, whichwas
correctly predicted by all consulted in silico prediction tools (Supp.
Table S1), pointing toward a neutral effect of this variant. This is sup-
ported by the fact that more recently a heterozygous PALB2 muta-
tion c.3362delGwas identified in this patient.
- BRCA2 c.8488-14A > G leads to aberrant splicing. This results from
the creation of a cryptic spice site, predicted by all tools consulted,
and a reduction in strength of the WT splice site, only predicted by
MES. The aberrant transcript contains an out of frame insertion of
the last 13 nucleotides of intron 19: r.8432_8433ins8433-13_8433-
1; p.(Trp2830Hisfs*19) (Supp. Table S1 and Figure 4D).
None of the five tested exonic variants outside the Cartegni con-
sensus region [two in BRCA1: c.1878A > G (p. = ) & c.4115G > A;
p.(Cys1372Tyr) and three in BRCA2: c.3326C > T; p.(Ala1109Val),
c.4899C > G; p.(Ile1633Met) & c.6313A > G; p.(Ile2105Val)] affected
mRNA splicing (Supp. Table S1). However, the prediction tool Priors,
classified three variants [BRCA1 c.1878A > G (p. = ) & c.4115G > A;
p.(Cys1372Tyr); BRCA2 c.3326C > T; p.(Ala1109Val)] as “moderate
probability of pathogenicity from the creation of a de novo splice
donor” (score 0.3). ∆ESRseq scoring predicted a splicing effect for
BRCA2 c.3326C > T and BRCA1 c.4115G > A (∆ESRseq scores below
−0.663). ESEfinder and RESCUE-ESE predicted both disruption and/or
creation of a new ESE for every variant except for BRCA2 c.4899C>G.
Furthermore, BRCA1 c.4115G > A was predicted to activate a cryptic
donor site at position c.4112. However, this cryptic donor site was not
strong enough to competewith theWTsplice site. Noneof the variants
were predicted to have an effect due to an altered protein structure
(Prior missense score: 0.02).
3.4 Identification ofmultiple cryptic donor sites
within the large exon 11 of BRCA2 in case of
interruption of theWT exon 11 donor site
cDNA analysis in lymphocytes of a patient heterozygous for the
BRCA2 tandem duplication c.426+415_4780dup{insGATCGCAGTGA}
revealed a complex splicing pattern (Figure 5). The major effects are
the inclusion of a cryptic exon in intron 4 (r.425+415_426-209), skip-
ping of exon 11 and aberrant transcripts due to the activation of two
cryptic donor siteswithin exon11: c.2398andc.3550.All combinations
observed are out of frame.
We evaluated if the cryptic donor sites at c.2398 and c.3550 were
also activated in a patientwith the substitutionBRCA2 c.6841+1G>C,
inactivating the WT donor site of exon 11. Besides skipping of exon
11, several other aberrant transcripts were observed. Also in this
patient, the cryptic splice donor sites at c.2398 and c.3550 are acti-
vated, resulting in the skip of respectively 4,443 and 3,291 nucleotides
from the 3′part of exon 11: r.2399_6841del; p.(Asn801_Gly2281del)
(Figure 2D) and r.3551_6841del; p.(Thr1185_Gly2281del) (Figure 2E),
respectively. The activation of c.2398 leads to a band of 1,038 bp, vis-
ible on the gel (Figure 2A), which was confirmed by direct sequenc-
ing. No band in concordance with activation of c.3550was observed in
the initial RT-PCR. However, by means of allele specific primers (Supp.
Table S1), we could confirm the activation of this particular cryptic
splice site.
4 DISCUSSION
Weevaluated the effect at the cDNA level of 21VUS in BRCA1 (n= 11)
andBRCA2 (n=10) and demonstrated aberrant splicing for 12 variants
(seven inBRCA1 and five inBRCA2). In addition,weevaluated the effect
of a large tandem duplication in BRCA2, with breakpoints in intron 4
and exon 11.
By analyzing controls in all assays, we verified that none of the
detected aberrant BRCA2 transcripts were reported as naturally
occurring alternative transcripts (Fackenthal et al., 2016). A skip of
BRCA2 exon 11 was also observed in controls, though be it at very
low level (Figure 2). Some of the variants studied in BRCA1, lead
to a strong upregulation of low abundant naturally occurring tran-
scripts in our patients: skip of exon 2 (r.-19_80), exon 3 (r.81_134del),
exon 13 and 14 (r.4358_4675del), exon 14 (r.4485_4675del) and
exon 17 (r.5075_5152del) but none of these are considered as nat-
urally occurring in frame RNA isoforms that may rescue gene func-
tionality (cfr. ENIGMA BRCA1/2 Gene Variant Classification Crite-
ria v2.4, Table 6—downloaded from: https://enigmaconsortium.org/
wp-content/uploads/2016/01/ENIGMA_Rules_2017-05-09.pdf).
mRNA splicing assays yield insights in the exact aberrant tran-
script, which may in turn shed light on the clinical importance of
the variant. The majority of the tested splicing variants lead to a
frameshift and the creation of a PTC and are therefore expected to
be degraded by NMD (Baert et al., 2016; Perrin-vidoz, Sinilnikova,
Stoppa-lyonnet, Lenoir, & Mazoyer, 2002; Ware et al., 2006). Aber-
rant BRCA1 transcripts can escape NMDwhen the PTC is located near
the C-terminus or near the translation initiation codon (Perrin-vidoz
et al., 2002). Based on this rule, BRCA1 c.134+5G > T and BRCA1
c.5468-1G > A may escape NMD. Translation of the transcript gener-
ated from the BRCA1 c.134+5G > T allele would result in only a very
small, most likely non-functional, protein (p.(Cys27*)). BRCA1 c.5468-
1G > A leads to an aberrant transcript with a stop codon at amino
acid position p.1825 in the last exon. Unfortunately, cultured lym-
phocytes without puromycin were not available to check the expres-
sion of the aberrant transcript in the absence of NMD inhibition. But
even if this transcript avoids NMD, two nonsense mutations result-
ing in a stop codon downstream of amino acid 1825 (c.5503C > T;
p.(Arg1835*) and c.5559C > A; p.(Tyr1853*)) are also considered as
pathogenicmutations (seeClinVar database entries 55601and55629)
and evasion ofNMDwas demonstrated for both variants (Perrin-vidoz
et al., 2002).
A pathogenic effect for BRCA1 c.80+5G > A is expected as the
AUG translation initiation codon is lost due to the skip of exon 2.
Interruption of the translation initiation codon by a substitution has
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F IGURE 4 Results of in vitro mRNA analysis of four BRCA2 variants. Schematic representation and sequencing results of four BRCA2 variants
leading to aberrant splicing with the x illustrating the position of the variant and controls. Nucleotide and exon numbering for cDNA is based on
NCBI entry NM_000059.3
previously been classified as deleterious (ClinVar ID: 54432, 54745,
54746, 55072, and 267523).
BRCA1 c.5152+2dupT, leads to an in frame skip of exon 17
(r.5075_5152del; p.(Arg1692_Trp1717delinsGly)). Several naturally
occurring transcripts lack exon 17 (Colombo et al., 2014), but in our
sequencing data the skip of exon 17 was only very obvious in the
patient heterozygous for c.5152+2dupT (see Figure 1C). A transcript
lacking an in frame exon will avoid NMD. But a skip of exon 17 (amino
acids: 1692_1718) leads to disruption of a large part of the first BRCT
domain (amino acids 1671_1745), required for several functions of the
BRCA1 protein (Roy et al., 2012). Several missense variants in these
BRCT repeats lead to impaired folding (Glover, 2006; Lovelock et al.,
2006, 2007) and shown to be deleterious based on multifactorial like-
lihood analysis (Lindor, Goldgar, Tavtigian, Plon, & Couch, 2013). Sim-
ilarly, BRCA1 c.5468-1G > A; p.(Ala1823Valfs*2) results in loss of the
last 31 amino acids of the second BRCT repeat (amino acids 1,779–
1,854) and is therefore expected to cause improper folding of this
motif. The p.Val1838Glu variant located in this domain is a proven class
5 variant (Lindor et al., 2013). Binding of several interaction partners
might thus be impaired by these two variants, and a deleterious effect
may be further confirmed by functional assays.
Aberrant transcripts induced by BRCA2 c.6841+1G > C are
all in frame (p.(Thr1185_Gly2281del), p.(Asn801_Gly2281del), and
p.(Leu638_Gly2281del)). However, the size of the deletions and the
location in the BRC repeat region, necessary for binding of RAD51
(Gudmundsdottir & Ashworth, 2006), suggest a pathogenic effect.
mRNA analysis of three variants situated in intron 19 of BRCA2
revealed different effects. Variants c.8488-9T>Gand c.8488-14A>G
resulted in aberrant splicing, whereas a variant situated in between
those two (c.8488-12A > G) did not impair proper mRNA splicing.
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F IGURE 5 RT-PCR results for the patient heterozygous for BRCA2 c.426+415_4780dup{ins GATCGCAGTGA}. A: Schematic representation
of the complex tandem duplication. B–D: RT-PCR combining a forward primer in exon 11 (c.3183_ 3202) and a reverse primer in exon 10
(c.1261_1242) (as indicated in panel a), did not result in a PCR product in two controls but resulted in two fragments in the patient with the dupli-
cation (panel B: three replicates shown for the patient with the duplication in BRCA2). Sequencing results for these two fragments are shown in
panels C and D. C: The largest PCR product contained all nucleotides from the start of the primer till c.4780 (the presumed breakpoint in exon
11), an insertion of 11 nucleotides (GATCGCAGTGA), followed by 293 nucleotides from intron 4 (from c.425+415 to c.426-209) and continued
by all nucleotides from exon 5 to position c.4780 in exon 11; D: a smaller fragment was produced by the activation of a cryptic splice site donor
at nucleotide position c.3550. This fragment does not contain nucleotides c.3551 to c.4780, the 11 bp sequence GATCGCAGTGA nor the 293
nucleotides between c.425+415 to c.426-209 from intron 4. E and F: RT-PCRwith a forward primer in exon 10 (c.1544_1565) and a reverse primer
in exon 7 (c.1078_1099) allowed identification of two additional transcripts: (E) sequencing revealed the activation of a cryptic splice site donor at
nucleotide position c.2398, followed by the insertion of 11 nucleotides (GATCGCAGTGA) and 293 nucleotides of intron 4 (c.425+415_426-209);
(F) in addition, a shorter aberrant fragment resulting from the complete skip of exon 11was obtained
Both c.8488-9T > G and c.8488-14A > G create a novel acceptor site,
whereas the natural splice acceptor site is relatively weak; a naturally
occurring skip of exon 20 has been demonstrated (Fackenthal et al.,
2016). The variant c.8488-12A > G does not result in a de novo “AG”
splice acceptor site, and did induce aberrant splicing. Only variants
in the canonical splice acceptor site of BRCA2 exon 20 (c.8488-1/2)
have previously been reported to result in exon skipping (ClinVar and
LOVD) (Fackenthal et al., 2016). We assume that the aberrant tran-
scripts induced by c.8488-9T>Gand c.8488-14A>Gwill be degraded
by NMD as NMD was demonstrated for all tested PTC-introducing
mutations in BRCA2, evenwhen the stop codon is situated towards the
C-terminal end (Ware et al., 2006). Even in the absence of NMD how-
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ever, the predicted proteins with a frameshift starting from amino acid
2830, will lack most of the BRCA2 DNA binding domain (amino acids
2481_3186), critical for BRCA2 functionality.
Out of the seven tested exonic variants studied, only two (BRCA1
c.4674A>G&BRCA2 c.517G>C) resulted in aberrant splicing.BRCA1
c.4674A>G, located in the second last nucleotide of exon 14, resulted
in aberrant splicing due to an abolished WT splice donor site and an
activated a cryptic (GC) donor site upstream at position c.4664, only
predicted by SSF (Supp. Table S1). BRCA2 c.517G > C is located in the
first nucleotide of exon 7 and induces aberrant splicing due to loss of
the natural splice site. However, splice site prediction tools demon-
strate only a marginal decrease in 3′ splice site strength (Supp. Table
S1). The skip of exon 7 (r.517_631del; p.(Gly173Serfs*19)) is likely to
undergo degradation of the transcript by NMD. A variant at the same
position (c.517G > T) was previously tested using both minigene and
RNA splicing analysis and also resulted in skipping of exon 7 (Gail-
drat et al., 2012). A higher than expected presence of splicing muta-
tions is detected in exon 7 of BRCA2. This exon is characterized by the
presence of ESE's and the combination with relatively weak natural
splice sites explains the high number of splicing variants in this exon (Di
Giacomo et al., 2013).
In contrast, no such variants have been reported in the large exons
10/11 of BRCA1/2. None of the four variants in the large exons stud-
ied here, showed improper splicing.∆ESRseq scoringwas used to eval-
uate regulatory elements in these exons. Based on the experimen-
tally determined cut-off of −0.6331 for variants in BRCA2 exon 7 (Di
Giacomo et al., 2013), aberrant splicing was a priori not expected for
two out of three studied BRCA2 exon 11 variants (∆ESRseq score for
c.4899C > G = 0.1009 and for c.6313A > G = 0.8822; Supp. Table
S1). However, for BRCA2 c.3326C > T and BRCA1 c.4115G > A the
∆ESRseq scores of respectively −2.9402 and −1.3814 would imply an
effect on exonic splice regulation which could not be demonstrated by
mRNA analysis. Therefore, the cut-off, experimentally determined for
variants in BRCA2 exon 7, containing a large number of ESE's in com-
bination with weak splice donor and acceptor sites, may not be appli-
cable for variants in other exons. Furthermore, neither the results of
ESEfinder nor the results of RESCUE-ESE were concordant with the
mRNA results for exonic variants included in this study. This illustrates
the limitedpredictive valueof these tools, although somemaybeuseful
for the evaluationof variants in exons enriched for exonic splicing regu-
lators (like BRCA2 exon 7,MLH1 exon 10, BRCA1 exon 6, CFTR exon 12,
andNF1 exon 46 (historical numbering: 37) (Soukarieh et al., 2016)).
To date, no known DNA variations inducing aberrant splicing of
BRCA2 exon 11 have been reported. Here, we detected the activation
of two cryptic splice donor sites at c.2398 and c.3550 in the absence of
theWT splice site by evaluating the impact on pre-mRNA splicing of a
large tandem duplication with a breakpoint 2061 bp upstream of the
WT donor site. Activation of both cryptic splice donor sites was con-
firmed in a patient with a substitution abolishing the WT splice donor
site of exon 11 (c.6841+1G > C). Scanning exon 11 with in silico pre-
diction tools available through Alamut 2.8.1 revealed several alterna-
tive cryptic splice site donors, but none of them were activated in the
patient with c.6841+1G>C. The activation of the cryptic splice donor
sites at positions c.2398 and c.3550 might be due to ESE motifs, lying
in close vicinity to the activated splice donor sites (Caceres, Hurst,
Cáceres, & Hurst, 2013; Ke et al., 2011). The influence of possible
ESE's on the cryptic splice site c.3550 and c.2398 should be further
experimentally validated (Di Giacomo et al., 2013; Raponi et al., 2014).
Knowledge on potentially activated splice sites in case of inactivation
of the WT site, may be important to design adequate BRCA2 ASOs
(antisense oligonucleotides), which have been proposed as a promis-
ing avenue to prevent resistance to PARP inhibitor therapy in sev-
eral tumor types (Rytelewski et al., 2016) or as potential therapeu-
tic anti-cancer agent in combination with cisplatin (Rytelewski et al.,
2014).
Another aim of this study was to test the performance of in sil-
ico prediction tools. For variants outside the canonical splice sites
but within the Cartegni consensus region, Adaboost and Random For-
est outperformed the tools integrated in Alamut (cfr. BRCA2 c.7618-
6G>T&c.8488-12A>G). Thedata fromAdaboost andRandomForest
are extracted from dbscSNV (Liu, Wu, Li, & Boerwinkle, 2016), which
currently only include data on substitutions within the Cartegni con-
sensus regions. For all variants studied and located in these regions, the
predictions were accurate. However, these programs provide only one
score. If this score is higher than 0.6, aberrant splicing is expected but
they do not provide an indication on the potential activation/creation
of cryptic splice sites; effects need to be studied by cDNA analysis.
The classic in silico prediction tools remain very useful for the evalu-
ation of intronic variants outside the Cartegni consensus region: aber-
rant scores were obtained for all variants leading to mis-splicing, in
agreement with previous studies suggesting that cDNA analysis is not
required for intronic variants if no effect on splicing is predicted by
multiple in silico prediction tools (Théry et al., 2011; Vreeswijk et al.,
2009).
Priors assesseswhether pathogenicity of amissense variant ismore
likely to originate from the amino acid substitution or a splicing defect
(Vallée et al., 2016). Of all exonic variants included in this study Pri-
ors gave the highest score for impaired splicing (0.34) for BRCA1
c.4674A > G & BRCA2 c.517G > C, and both variants lead to aberrant
splicing. However, this score is only marginally higher compared with
those for other variants [BRCA1 c.1878A > G (p. = ) & c.4115G > A;
p.(Cys1372Tyr) andBRCA2 c.3326C>T; p.(Ala1109Val)] not leading to
aberrant splicing (all with a Priors score of 0.3). A validation study on
a large number of exonic variants would allow to determine a thresh-
old for the Priors tool (currently not integrated in Alamut) abovewhich
a strong correlation between in silico prediction and aberrant mRNA
splicing exists.
To conclude, we confirmed aberrant splicing leading to disrup-
tion of functionally important domains for 12 out of 21 tested
DNA alterations, suggesting that these variants may be associ-
ated with a pathogenic effect. One limitation of the study is that
we were not able to assess allele-specific transcript expression
for all variants, which is a prerequisite of ENIGMA to definitively
classify a variant as (likely) pathogenic (https://enigmaconsortium
.org/wp-content/uploads/2016/01/ENIGMA_Rules_2017-05-09.pdf).
Two novel in silico prediction tools, Adaboost and Random Forest,
performed very well in our cohort, indicate which substitutions in the
Cartegni consensus region are expected to lead to aberrant splicing,
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but can currently not be used for variants outside these regions and
are only suitable for the evaluation of substitutions. Our study is the
first to reveal actively used cryptic splice donor sites within the large
exon 11 of BRCA2. This finding opens perspectives for new research
on the identification of cis and trans acting factors involved in correct
splicing of this large exon.
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